Foresite Capital is a remarkable healthcare growth equity company. It offers growth capital to the upcoming health care champions, in both public and private markets, with disruptive products and also services. The company is based in San Francisco and also has a workstation in the New York. Jim Tananbaum is lucky to hold the top ranks in the firm. He works as the Managing Director, Principal Executive Officer, as well as the Managing Director of this firm.
Foresite Capital is delighted to welcome a great talent into their workforce. Dr. He is the new entrant in the company. Dr. He brings her rich knowledge in genomics, and her leadership record is unmatched. Previously, she has worked at Illumina where she championed the firm’s worldwide protein reagent modernization. Prior to joining Illumina, she also championed the development of the firm’s single molecular chemistry. More so, in her early years of her career, she worked in the pharmaceutical sector where she focused on the development of molecular and antibody drugs that targeted cancer and immune ailments. She holds an undergraduate qualification from Nankai University and a doctorate in Protein biophysics. Moreover, she has over 20 publications in the field of healthcare modernization.
Being an industry leader for 25 years, Jim Tananbaum is an investor who focuses on building franchises within the healthcare sector. One of the core achievements is when he was the co-founder of the GeITex pharmaceuticals. During this time, they brought two drugs into the field which sold for $1.6billion. He is also a co-founder of Prospective Venture Partners II and III and Theravance, Inc.
Jim Tananbaum holds both Bachelor of Science and Bachelors of Science in Electrical Engineering undergraduate qualifications from Yale University. Also, he also holds an M.B.A and M.D from Harvard University. He is proud to have worked on the advisory committees and boards to various institutions, among them, Yale School of Engineering and Harvard. Recently, he has made a huge investment in the Allergen Research Firm. Mr. Jim continues to make headlines for his huge medical field investments which include Unicorn Intarcia Therapeutics, diabetes treatments, and Juno Therapeutics.